Pharmaceuticals, Biotechnology & Life Sciences

Insider buy: Cohlhepp Ryan’s March 3 purchase of Bicara shares shows confidence in the company’s pipeline and strong investor demand, hinting at future upside.

Absci insiders buy 800k+ shares, signaling confidence amid synthetic‑biology upside; investors weigh bullish moves against unprofitability and market volatility.

Ionis insider buys signal optimism for its RNA‑targeted pipeline—analyze the trade patterns, regulatory hurdles, and orphan‑drug prospects for smart investment decisions.

CEO’s zero‑cost RSU buy fuels insider confidence in Tectonic Therapeutics’ gene‑therapy pipeline and potential upside, but investors must weigh clinical milestones and FDA approvals.

Pfizer insiders boost long‑term stakes while selling a few shares for taxes, signalling confidence in its pipeline, value‑based model, and tech‑driven growth.

Monte Rosa insiders sell shares for tax reasons, yet the company’s biotech pipeline and high valuation keep investor focus on long‑term prospects, not short‑term trades.

CEO’s $3.26 share buy at Edesa Biotech signals strong confidence, but investors must watch Phase II results, potential dilution, and regulatory milestones for real upside.

Inovio’s insider buying spree signals strong confidence in its DNA‑vaccine pipeline—learn how CEO moves, Akeso partnership, and future milestones could boost value.

United Therapeutics insider trades signal a cautious yet optimistic move: CEO and EVP buy at 10‑b‑5‑1 prices, hinting at future growth from upcoming prostacyclin data.

CEO Reicin Alise’s recent purchase of 2,500 Tectonic Therapeutic shares shows executive confidence, hinting at future gene‑therapy milestones and a potential upside for investors.